Statements (30)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
small molecule |
| gptkbp:approvalYear |
2022
|
| gptkbp:approvedBy |
gptkb:United_States
gptkb:FDA |
| gptkbp:ATCCode |
C01EB25
|
| gptkbp:brand |
gptkb:Camzyos
|
| gptkbp:CASNumber |
1642288-47-8
|
| gptkbp:chemicalClass |
pyrimidine derivative
|
| gptkbp:contraindication |
pregnancy
concurrent use with certain CYP2C19 or CYP3A4 inhibitors |
| gptkbp:developedBy |
gptkb:Bristol_Myers_Squibb
gptkb:MyoKardia |
| gptkbp:hasMolecularFormula |
C15H19N3O2
|
| https://www.w3.org/2000/01/rdf-schema#label |
mavacamten
|
| gptkbp:KEGGID |
D11760
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
cardiac myosin inhibitor
|
| gptkbp:molecularWeight |
273.33 g/mol
|
| gptkbp:PubChem_CID |
gptkb:CHEMBL3989989
71587765 DB15197 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
heart failure
dizziness syncope |
| gptkbp:UNII |
6Z5B6HVF6O
|
| gptkbp:usedFor |
hypertrophic cardiomyopathy
|
| gptkbp:bfsParent |
gptkb:MyoKardia
|
| gptkbp:bfsLayer |
7
|